What is HC Wainwright’s Estimate for LPTX FY2029 Earnings?

Leap Therapeutics, Inc. (NASDAQ:LPTX) – Research analysts at HC Wainwright issued their FY2029 EPS estimates for shares of Leap Therapeutics in a research report issued on Wednesday, January 29th. HC Wainwright analyst S. Ramakanth expects that the company will post earnings per share of ($0.29) for the year. HC Wainwright has a “Neutral” rating on the stock. The consensus estimate for Leap Therapeutics’ current full-year earnings is ($1.84) per share.

A number of other equities research analysts have also weighed in on LPTX. Robert W. Baird lowered Leap Therapeutics from an “outperform” rating to a “neutral” rating and lowered their price objective for the company from $9.00 to $1.25 in a report on Wednesday. Baird R W cut Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday.

Leap Therapeutics Stock Down 12.1 %

Shares of NASDAQ:LPTX opened at $0.57 on Thursday. Leap Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $4.79. The firm’s 50-day simple moving average is $2.82 and its 200-day simple moving average is $2.75. The company has a market cap of $21.90 million, a price-to-earnings ratio of -0.30 and a beta of 0.17.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Valence8 US LP acquired a new stake in shares of Leap Therapeutics in the third quarter valued at approximately $48,000. HighTower Advisors LLC purchased a new stake in Leap Therapeutics in the 3rd quarter valued at approximately $65,000. HB Wealth Management LLC grew its holdings in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after buying an additional 26,150 shares during the last quarter. Marshall Wace LLP increased its position in Leap Therapeutics by 268.2% during the second quarter. Marshall Wace LLP now owns 79,758 shares of the company’s stock worth $156,000 after buying an additional 58,094 shares in the last quarter. Finally, Exome Asset Management LLC acquired a new position in shares of Leap Therapeutics in the third quarter worth $264,000. 30.46% of the stock is currently owned by institutional investors and hedge funds.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.